Disease Overview：Non-Hodgkin lymphoma（NHL）
Non-Hodgkin lymphoma (NHL) is a heterogeneous group of malignant neoplasms originating from lymphoid tissue—primarily B cells, though T-cell and NK-cell variants also occur. Unlike Hodgkin lymphoma, NHL lacks Reed-Sternberg cells and encompasses over 90 distinct subtypes, ranging from indolent (e.g., follicular lymphoma, marginal zone lymphoma) to aggressive (e.g., diffuse large B-cell lymphoma, mantle cell lymphoma). Clinical presentation varies widely but commonly includes painless lymphadenopathy, systemic “B symptoms” (fever, night sweats, weight loss), and extranodal involvement in gastrointestinal, cutaneous, or central nervous system sites. Diagnosis relies on histopathology, immunohistochemistry, flow cytometry, and molecular profiling—including MYC, BCL2, and BCL6 rearrangements—to guide risk stratification and therapy selection. Treatment modalities include immunochemotherapy (e.g., R-CHOP), targeted agents (e.g., BTK inhibitors, PI3K inhibitors), bispecific antibodies, CAR-T cell therapy, and consolidative radiotherapy or stem cell transplantation, tailored to subtype, stage, and patient fitness.
China offers compelling advantages for international patients seeking NHL management. Leading tertiary hospitals—such as Peking Union Medical College Hospital, Fudan University Shanghai Cancer Center, and Sun Yat-sen University Cancer Center—house nationally certified hematologic oncology teams with extensive experience in complex lymphoma subtyping and novel therapeutics. These centers utilize next-generation sequencing, digital pathology platforms, and FDA/EMA-approved CAR-T products (including domestically developed anti-CD19 constructs like Equecabtagene Autoleucel), achieving progression-free survival rates comparable to Western benchmarks. Notably, treatment costs in China are typically 40–60% lower than in the US or EU without compromising clinical rigor—R-CHOP cycles average USD $8,000–$12,000; autologous stem cell transplant, USD $35,000–$45,000; and CAR-T therapy, USD $120,000–$150,000—while maintaining strict adherence to NCCN and ESMO guidelines. As a dedicated medical tourism agency, we facilitate seamless access to these resources: coordinating appointments with bilingual hematologists, verifying hospital accreditation and treatment protocols, providing itemized, transparent pricing upfront, and delivering end-to-end support—from visa assistance and medical translation to accommodation logistics and post-treatment follow-up coordination.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Non-Hodgkin Lymphoma (NHL) — Hematology Department
I. Non-Surgical / Conservative / Medication-Based Therapies
*Indicated for most indolent and many aggressive subtypes; selection based on histology, stage (Ann Arbor), IPI score, age, and organ function.*
- •First-Line Chemoimmunotherapy (e.g., R-CHOP)
- *Itemized Cost (USD, Grade 3A Hospital)*: • Rituximab (375 mg/m² × 6 cycles): $1,850–$2,200 • Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (per cycle): $420–$580 • Total 6-cycle regimen: $4,370–$5,540 - *Supportive Care & Monitoring*: • CBC, LDH, β2-microglobulin, renal/liver panel (per cycle): $45–$65 • CT/PET-CT staging & interim response assessment (2 scans): $1,120–$1,380
- •Targeted Oral Therapy (e.g., Ibrutinib for MCL/CLL-type NHL)
- *Monthly cost (420 mg/day)*: $1,950–$2,100 - *Required monitoring*: ECG, CBC, liver enzymes (monthly): $28–$42/month
II. Procedural / Interventional Options
*All procedures performed in hematology/oncology units; bone marrow biopsy is standard diagnostic & surveillance tool.*
- •Autologous Stem Cell Transplant (ASCT)
- *Preoperative Workup (mandatory)*: • Cardiac echo + pulmonary function test: $210 • Bone marrow biopsy + flow cytometry + cytogenetics: $340–$410 - *Procedure Cost (including mobilization, apheresis, conditioning [BEAM], reinfusion, 28-day inpatient care)*: $14,800–$16,300
- •Allogeneic Stem Cell Transplant
- *Total cost (including donor workup, conditioning [Flu/Bu], GVHD prophylaxis, 45-day admission)*: $28,600–$32,400
III. Special/Complex Condition Management
- •Primary CNS Lymphoma: High-dose methotrexate IV + intrathecal therapy + whole-brain radiotherapy (if indicated): $7,900–$9,200 (includes serial CSF analysis, MRI brain q4w)
- •Lymphoma with Hepatic/Renal Infiltration: Dose-adjusted EPOCH-R + therapeutic drug monitoring: $6,100–$7,400 (adds pharmacokinetic assays: $180/test)
IV. Quick Selection Guide
- •Elderly (>70) / Frail / Comorbid (CVD, CKD): Start with R-miniCHOP ($3,200–$3,900) + growth factor support
- •Young, Fit, Aggressive NHL (DLBCL): R-CHOP × 6 → interim PET-CT → consider ASCT if high IPI or early progression ($19,200 total)
- •Budget-Constrained (<$5,000): Rituximab monotherapy ($1,850–$2,200) + watchful waiting for indolent subtypes (follicular grade 1–2)
- •Relapsed/Refractory after 2 lines: CAR-T (e.g., relmacabtagene autoleucel) — available at 5 national centers; $38,500–$41,200 (includes leukapheresis, manufacturing, 30-day monitoring)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Non-Hodgkin lymphoma Medical Vacation Packages
Curated transparent all-inclusive packages combining Non-Hodgkin lymphoma treatment with China top medical destinations:
